title: Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
abstract: Cancer is a common disease that is a leading cause of death worldwide. Currently, early detection and novel therapeutic strategies are urgently needed for more effective management of cancer. Importantly, protein profiling using clinical proteomic strategies, with spectacular sensitivity and precision, offer excellent promise for the identification of potential biomarkers that would direct the development of targeted therapeutic anticancer drugs for precision medicine. In particular, clinical sample sources, including tumor tissues and body fluids (blood, feces, urine and saliva), have been widely investigated using modern high-throughput mass spectrometry-based proteomic approaches combined with bioinformatic analysis, to pursue the possibilities of precision medicine for targeted cancer therapy. Discussed in this review are the current advantages and limitations of clinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical proteomics-driven precision medicine for targeted cancer therapy.
authors.affiliation: a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital , Sichuan University, and Collaborative Innovation Center for Biotherapy , Chengdu , P.R. China.|b Department of Neurology , The Affiliated Hospital of Hainan Medical College , Haikou , Hainan , P.R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.affiliation: a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital , Sichuan University, and Collaborative Innovation Center for Biotherapy , Chengdu , P.R. China.
authors.forename: Kui
authors.initials: K
authors.lastname: Wang
authors.affiliation: b Department of Neurology , The Affiliated Hospital of Hainan Medical College , Haikou , Hainan , P.R. China.
authors.forename: Qifu
authors.initials: Q
authors.lastname: Li
authors.affiliation: a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital , Sichuan University, and Collaborative Innovation Center for Biotherapy , Chengdu , P.R. China.|c Department of Biochemistry and Molecular Biology , Monash University , Clayton , Australia.
authors.forename: Edouard C
authors.initials: EC
authors.lastname: Nice
authors.affiliation: b Department of Neurology , The Affiliated Hospital of Hainan Medical College , Haikou , Hainan , P.R. China.
authors.forename: Haiyuan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital , Sichuan University, and Collaborative Innovation Center for Biotherapy , Chengdu , P.R. China.|b Department of Neurology , The Affiliated Hospital of Hainan Medical College , Haikou , Hainan , P.R. China.
authors.forename: Canhua
authors.initials: C
authors.lastname: Huang
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D040901:Proteomics / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor
keywords: Clinical proteomics; cancer therapy; drug target identification; mass spectrometry; precision medicine